12.2 Clinical Biochemistry, Molecular Genetics & Microbiology
Key Takeaways
- Competitive enzyme inhibitors increase K_m without altering V_max, while non-competitive inhibitors decrease V_max without affecting K_m.
- Autosomal dominant disorders carry a 50% transmission risk per offspring regardless of sex; autosomal recessive disorders carry a 25% recurrence risk among carrier parents.
- Acute Intermittent Porphyria results from porphobilinogen deaminase deficiency (causing neurovisceral attacks without cutaneous symptoms), whereas Porphyria Cutanea Tarda is caused by uroporphyrinogen decarboxylase deficiency (causing blistering photosensitivity).
- Targeted molecular translocation t(15;17)(q22;q12) generates the PML-RARA fusion protein in acute promyelocytic leukemia, conferring sensitivity to all-trans retinoic acid (ATRA).
- Extended-spectrum beta-lactamases (ESBLs) confer resistance to penicillins, cephalosporins, and monobactams, requiring carbapenems as first-line therapy.
12.2 Clinical Biochemistry, Molecular Genetics & Microbiology
Enzyme Kinetics, Inborn Errors of Metabolism & Metabolic Integration
Clinical biochemistry in internal medicine requires an advanced comprehension of enzyme kinetics, metabolic flux control, and specific enzymatic defects causing metabolic diseases.
Michaelis-Menten Kinetics & Enzyme Inhibition
Enzyme reaction rates depend on substrate concentration ($[S]$), obeying Michaelis-Menten kinetics: Where $V_{max}$ is the maximum reaction velocity at saturating substrate levels, and $K_m$ (the Michaelis constant) represents the substrate concentration at which reaction velocity is half-maximal ($0.5 \times V_{max}$). $K_m$ is inversely proportional to enzyme-substrate affinity.
Reversible enzyme inhibitors alter kinetic parameters in clinically distinct patterns:
- Competitive Inhibition: The inhibitor binds reversibly to the active site, competing directly with substrate.
- Kinetic Effect: Increases $K_m$ (decreases apparent affinity); $V_{max}$ remains unchanged. High substrate concentrations can fully overcome competitive inhibition.
- Clinical Example: Statins (e.g., atorvastatin) competitively inhibit HMG-CoA reductase; methotrexate competitively inhibits dihydrofolate reductase.
- Non-Competitive Inhibition: The inhibitor binds to an allosteric site regardless of whether substrate is bound.
- Kinetic Effect: Decreases $V_{max}$; $K_m$ remains unchanged. Increasing substrate concentration cannot overcome non-competitive inhibition.
- Clinical Example: Cyanide non-competitively inhibits mitochondrial cytochrome c oxidase (complex IV).
- Uncompetitive Inhibition: The inhibitor binds exclusively to the enzyme-substrate ($ES$) complex.
- Kinetic Effect: Decreases both $K_m$ and $V_{max}$ proportionally.
Clinical Porphyrias: Biochemical Differentiation
The heme biosynthetic pathway involves eight sequential enzymatic steps. Inherited deficiencies produce distinct porphyria syndromes, broadly divided into acute neurovisceral porphyrias and cutaneous photosensitive porphyrias:
- Acute Intermittent Porphyria (AIP): Autosomal dominant deficiency of Porphobilinogen Deaminase (PBGD) (also known as HMBS).
- Clinical Features: Recurrent severe abdominal pain, autonomic instability (hypertension, tachycardia), peripheral neuropathy, and neuropsychiatric symptoms triggered by cytochrome P450-inducing drugs, fasting, or stress.
- Key Laboratory Finding: Markedly elevated urine porphobilinogen (PBG) and delta-aminolevulinic acid (ALA). No cutaneous lesions or photosensitivity.
- Porphyria Cutanea Tarda (PCT): Deficiency of Uroporphyrinogen Decarboxylase (UROD) (inherited or acquired due to iron overload, hepatitis C, alcohol, or estrogen exposure).
- Clinical Features: Fragile skin, blistering cutaneous photosensitivity on sun-exposed areas (dorsum of hands, face), hyperpigmentation, and hypertrichosis.
- Key Laboratory Finding: Elevated urinary uroporphyrin I/III ratio and reddish-brown urine under Wood's lamp.
Patterns of Human Genetic Inheritance & Molecular Diagnostics
MRCPI Part I candidates must accurately interpret pedigree diagrams, calculate transmission risks, and understand cytogenetic abnormalities.
Mendelian & Non-Mendelian Inheritance Mechanics
| Inheritance Mode | Offspring Transmission Risk | Key Genetic Features | Clinical Exemplars |
|---|---|---|---|
| Autosomal Dominant | 50% for each child of an affected parent | Vertical transmission; males and females affected equally; variable expressivity and incomplete penetrance | Marfan syndrome (FBN1), Familial Hypercholesterolemia (LDLR), Huntington disease (HTT), Neurofibromatosis Type 1 (NF1) |
| Autosomal Recessive | 25% for carrier parents; 50% carriers; 25% unaffected | Horizontal transmission; consanguinity increases risk; skipped generations common | Cystic Fibrosis (CFTR), Hemochromatosis (HFE), Sickle Cell Disease (HBB), Wilson Disease (ATP7B) |
| X-Linked Recessive | 50% of sons of carrier mothers affected; 0% male-to-male transmission | Affected males far exceed females; daughters of affected males are obligate carriers | Hemophilia A (F8) & B (F9), Duchenne Muscular Dystrophy (DMD), G6PD Deficiency |
| X-Linked Dominant | Affected male passes to 100% of daughters, 0% of sons; affected female passes to 50% offspring | Females affected twice as often as males; often lethal in males in utero | Alport syndrome (COL4A5), Hypophosphatemic Rickets (PHEX), Rett syndrome (MECP2) |
| Mitochondrial (Maternal) | Passed from affected mother to 100% of children; 0% transmission from affected fathers | Variable severity due to heteroplasmy (mix of wild-type and mutant mtDNA) | MELAS, MERRF, Leber Hereditary Optic Neuropathy (LHON) |
Trinucleotide Repeat Expansion & Anticipation
Certain autosomal dominant or X-linked disorders result from unstable trinucleotide repeat expansions within critical genes. Anticipation describes the phenomenon where disease severity increases and age of onset decreases in successive generations due to expansion during gametogenesis.
- Huntington Disease: CAG repeat expansion in $HTT$ gene (normal <26; fully penetrant disease >40 repeats). Paternal transmission causes dramatic expansion.
- Fragile X Syndrome: CGG repeat expansion in $FMR1$ gene (normal <55; full mutation >200 repeats with hypermethylation).
- Myotonic Dystrophy Type 1: CTG repeat expansion in $DMPK$ gene. Maternal transmission causes severe congenital forms.
Cytogenetics & Molecular Diagnostics
- Fluorescent In Situ Hybridization (FISH): Uses fluorescent DNA probes to detect chromosomal microdeletions (e.g., 22q11.2 deletion in DiGeorge syndrome) or translocations.
- Diagnostic Translocations in Hematology:
- t(9;22)(q34;q11): Philadelphia chromosome creating $BCR\text{-}ABL1$ fusion tyrosine kinase in Chronic Myeloid Leukemia (CML); treated with imatinib.
- t(15;17)(q22;q12): Creates $PML\text{-}RARA$ fusion protein in Acute Promyelocytic Leukemia (APML); treated with all-trans retinoic acid (ATRA) and arsenic trioxide.
- t(8;14)(q24;q32): Translocates $MYC$ proto-oncogene to Ig heavy chain locus in Burkitt Lymphoma.
- t(11;14)(q13;q32): Overexpresses Cyclin D1 ($CCND1$) in Mantle Cell Lymphoma.
Clinical Microbiology, Antimicrobial Pharmacology & Resistance Mechanisms
Understanding pathogenic microorganisms and mechanisms of antimicrobial resistance is vital for systemic infection management.
Bacterial Classification & Diagnostic Algorithm
Bacterial identification relies on Gram staining, morphology, oxygen requirement, and biochemical testing:
- Gram-Positive Cocci:
- Catalase Positive: Staphylococci. Staphylococcus aureus is coagulase-positive; S. epidermidis and S. saprophyticus are coagulase-negative.
- Catalase Negative: Streptococci. Classified by hemolysis on blood agar:
- Alpha-hemolytic (partial green hemolysis): Streptococcus pneumoniae (optochin sensitive, bile soluble) and Viridans streptococci (optochin resistant).
- Beta-hemolytic (complete clear hemolysis): Group A Streptococcus pyogenes (bacitracin sensitive) and Group B Streptococcus agalactiae (bacitracin resistant).
- Gamma-hemolytic (no hemolysis): Enterococcus faecalis/faecium (grows in 6.5% NaCl, bile-esculin positive).
- Gram-Negative Bacilli:
- Lactose Fermenters (pink colonies on MacConkey agar): Escherichia coli, Klebsiella pneumoniae, Enterobacter.
- Non-Lactose Fermenters: Pseudomonas aeruginosa (oxidase positive, produces pyocyanin), Salmonella, Shigella, Proteus (oxidase negative).
Mechanisms of Antimicrobial Resistance
| Resistance Phenotype | Genetic Mechanism | Clinical Implications & Preferred Antimicrobials |
|---|---|---|
| Methicillin-Resistant S. aureus (MRSA) | Acquisition of $mecA$ gene encoding altered Penicillin-Binding Protein 2a (PBP2a) with low affinity for beta-lactams | Resistant to all penicillins, cephalosporins (except ceftaroline), and carbapenems. First-line treatment: Vancomycin, Daptomycin, or Linezolid. |
| Extended-Spectrum Beta-Lactamase (ESBL) | Plasmid-mediated $bla_{CTX-M}$, $bla_{TEM}$, or $bla_{SHV}$ genes hydrolyzing penicillins, cephalosporins, and aztreonam | Common in E. coli and K. pneumoniae. Inhibited by clavulanate/tazobactam in vitro, but Carbapenems (meropenem, ertapenem) remain drug of choice for invasive infections. |
| Vancomycin-Resistant Enterococcus (VRE) | Acquisition of $vanA$ or $vanB$ gene clusters altering peptidoglycan precursors from D-Ala-D-Ala to D-Ala-D-Lac | Renders vancomycin unable to bind peptidoglycan cell wall targets. First-line treatment: Linezolid or Daptomycin. |
| AmpC Beta-Lactamase | Chromosomally encoded inducible beta-lactamase in SPACE organisms (Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter) | Cephalosporins induce resistance during therapy. Preferred treatment: Cefepime or Carbapenems. |
MRCPI Exam Pearl: When selecting antifungal therapy for systemic mycoses, remember that Amphotericin B binds ergosterol forming membrane pores, Azoles (e.g., fluconazole, voriconazole) inhibit 14$\alpha$-demethylase (cytochrome P450 dependent enzyme preventing ergosterol synthesis), and Echinocandins (caspofungin, micafungin) non-competitively inhibit $\beta$-(1,3)-D-glucan synthase, disrupting fungal cell wall integrity.
A biochemical study investigates the kinetics of a novel pharmacological inhibitor designed to target a rate-limiting metabolic enzyme. Kinetic analysis in the presence of the inhibitor demonstrates an increased Michaelis constant (K_m) for the substrate, while the maximum reaction velocity (V_max) remains completely unchanged at high substrate concentrations. Which class of enzyme inhibition does this agent exhibit?
A genetics clinic evaluates a pedigree across four generations. An affected male patient passes the genetic trait to all six of his daughters, none of whom display skipped generations, but none of his four sons inherit the condition. Affected female offspring pass the condition to 50% of their sons and 50% of their daughters. Which mode of inheritance is demonstrated in this family?
A 34-year-old female presents with fatigue, mucosal bleeding, and widespread petechiae. Peripheral blood smear reveals leukopenia, severe thrombocytopenia, and abnormal promyelocytes containing abundant Auer rods. Cytogenetic testing confirms a balanced reciprocal translocation t(15;17)(q22;q12). Which fusion protein is generated by this abnormality, establishing the targeted indication for all-trans retinoic acid (ATRA) therapy?